<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010347</article-id><article-id pub-id-type="publisher-id">ACM-38157</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_10731065.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  椎间盘退变的机制及其治疗综述
  The Mechanism and Treatment of Intervertebral Disc Degeneration
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>嘉军</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>勇</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>德荣</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>建伟</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>华聪</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2302</fpage><lpage>2310</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    椎间盘退变(intervertebral disc degeneration, IVDD)是一个多因素的过程，其表现为表型和基因型的变化，导致椎管狭窄、脊柱不稳、腰腿痛等疾病。合成代谢与分解代谢的长期失衡导致椎间盘蛋白多糖和水合作用的逐渐丧失进而改变其组成，最终导致IVDD。目前对IVDD的处理只能缓解症状，无法从根本上解决椎间盘退变的情况。研究人员正在尝试确定造成椎间盘退变的各种因素以及再生策略。近期生物学方法在IVDD领域获得了推动力。本综述讲述了目前对椎间盘退变的理解，旨在提出促进椎间盘再生策略以及不同生物疗法的最新进展，如生长因子、细胞和基因疗法，这些疗法的潜力及结果也被广泛讨论。最初，椎间盘退变的治疗包括传统的保守治疗和手术治疗，通过人们不断地努力，将来生长因子、细胞和基因疗法可能被证明是非常有效的治疗IVDD的方法。
    Intervertebral disc degeneration is a multifactorial process, which manifests as changes in phenotype and genotype, leading to spinal stenosis, spinal instability, low back pain and other diseases. The long-term imbalance between anabolism and catabolism leads to the gradual loss of intervertebral disc proteoglycan and hydration, which changes its composition and ultimately leads to IVDD. The current treatment of IVDD can only relieve symptoms, and cannot fundamentally solve the situation of intervertebral disc degeneration. Researchers are trying to determine the various factors that cause intervertebral disc degeneration and regeneration strategies. Recent biological methods have gained momentum in the field of IVDD. This review describes the current understanding of intervertebral disc degeneration, and aims to propose strategies to promote intervertebral disc regeneration and the latest advances in different biological therapies, such as growth factors, cell and gene therapies. The potential and results of these therapies have also been widely discussed. Initially, the treatment of intervertebral disc degeneration included traditional conservative treatment and surgical treatment. Through continuous efforts, growth factor, cell and gene therapy may prove to be very effective treatments for IVDD in the future. 
  
 
</p></abstract><kwd-group><kwd>椎间盘，退变，治疗, Intervertebral Disc</kwd><kwd> Degeneration</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>椎间盘退变(intervertebral disc degeneration, IVDD)是一个多因素的过程，其表现为表型和基因型的变化，导致椎管狭窄、脊柱不稳、腰腿痛等疾病。合成代谢与分解代谢的长期失衡导致椎间盘蛋白多糖和水合作用的逐渐丧失进而改变其组成，最终导致IVDD。目前对IVDD的处理只能缓解症状，无法从根本上解决椎间盘退变的情况。研究人员正在尝试确定造成椎间盘退变的各种因素以及再生策略。近期生物学方法在IVDD领域获得了推动力。本综述讲述了目前对椎间盘退变的理解，旨在提出促进椎间盘再生策略以及不同生物疗法的最新进展，如生长因子、细胞和基因疗法，这些疗法的潜力及结果也被广泛讨论。最初，椎间盘退变的治疗包括传统的保守治疗和手术治疗，通过人们不断地努力，将来生长因子、细胞和基因疗法可能被证明是非常有效的治疗IVDD的方法。</p></sec><sec id="s2"><title>关键词</title><p>椎间盘，退变，治疗</p></sec><sec id="s3"><title>The Mechanism and Treatment of Intervertebral Disc Degeneration</title><p>Jiajun Zhang, Yong Liu, Derong Xu, Jianwei Guo, Huacong Wang</p><p>Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/14-1571593x4_hanspub.png" /></p><p>Received: Sep. 29<sup>th</sup>, 2020; accepted: Oct. 14<sup>th</sup>, 2020; published: Oct. 21<sup>st</sup>, 2020</p><p><img src="//html.hanspub.org/file/14-1571593x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Intervertebral disc degeneration is a multifactorial process, which manifests as changes in phenotype and genotype, leading to spinal stenosis, spinal instability, low back pain and other diseases. The long-term imbalance between anabolism and catabolism leads to the gradual loss of intervertebral disc proteoglycan and hydration, which changes its composition and ultimately leads to IVDD. The current treatment of IVDD can only relieve symptoms, and cannot fundamentally solve the situation of intervertebral disc degeneration. Researchers are trying to determine the various factors that cause intervertebral disc degeneration and regeneration strategies. Recent biological methods have gained momentum in the field of IVDD. This review describes the current understanding of intervertebral disc degeneration, and aims to propose strategies to promote intervertebral disc regeneration and the latest advances in different biological therapies, such as growth factors, cell and gene therapies. The potential and results of these therapies have also been widely discussed. Initially, the treatment of intervertebral disc degeneration included traditional conservative treatment and surgical treatment. Through continuous efforts, growth factor, cell and gene therapy may prove to be very effective treatments for IVDD in the future.</p><p>Keywords:Intervertebral Disc, Degeneration, Treatment</p><disp-formula id="hanspub.38157-formula6"><graphic xlink:href="//html.hanspub.org/file/14-1571593x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/14-1571593x8_hanspub.png" /> <img src="//html.hanspub.org/file/14-1571593x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>与椎间盘退变密切相关的症状中，腰痛(low back pain, LBP)是极为常见的一种，影响全球上亿人。全民中约有半数以上的人在他们生活中的某个时间有LBP，严重影响患者的生活质量，进而造成巨大的社会经济影响。LBP的病因是明确的、多因素且复杂的，但磁共振和组织学的数据显示：腰椎间盘突出症与椎间盘退变(IVDD)有着密切的联系，研究椎间盘退变的机制，将会加强人们对椎间盘退变性疾病的认识和理解。</p><p>椎间盘是由髓核(nucleus pulposus, NP)、纤维环(annulus fibrosus, AF)和软骨终板(cartilaginous end plate, CEP)组成的多组分组织结构，见图1。NP位于中心，是富含蛋白聚糖的亲水性凝胶状细胞外基质，主要由II型胶原和蛋白聚糖组成，其被由I型纤维组成的薄片状同心胶原环AF包绕。CEP通过薄层透明软骨将间盘上方和下方固定到相邻间盘的骨终板(bony end plates, BEPs)上 [<xref ref-type="bibr" rid="hanspub.38157-ref1">1</xref>]。</p><p>图1. 椎间盘的结构示意图</p></sec><sec id="s6"><title>2. IVDD的发病机制</title><p>IVDD的病因通常包括遗传因素和环境因素。通常IVDD的发生是由于细胞外基质(extracellular matrix, ECM)的分解代谢强于合成代谢。椎间盘退变的主要原因之一是供应到椎间盘细胞的营养的改变导致的缺氧和酸性pH影响了椎间盘细胞外基质合成和支持的能力 [<xref ref-type="bibr" rid="hanspub.38157-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref3">3</xref>]。环境危险因素也影响着IVDD的发病。一些不健康的生活方式包括缺乏运动、吸烟和职业暴露例如振动、机械负荷和严重创伤等是导致少数椎间盘退变的因素 [<xref ref-type="bibr" rid="hanspub.38157-ref4">4</xref>]。</p><p>通过几个基因的分析证实：遗传基因是与IVDD的发展有关的最普遍的危险因素。椎间盘的结构受到聚集蛋白聚糖(aggrecan, ACAN)、胶原蛋白(大肠杆菌，IX和XI)、透明质酸、纤连蛋白(fibronectin, FN)、蛋白多糖连接蛋白1 (hyaluronan and proteoglycan link protein1, HAPLN1)、血栓蛋白(thrombospondin, TBSP)、软骨中间层蛋白(cartilage intermediate layer protein, CILP)和无孢蛋白(asporin, ASPN)基因的多态性的影响 [<xref ref-type="bibr" rid="hanspub.38157-ref5">5</xref>]。多态性分解代谢基因，如基质金属蛋白酶(Matrix Metalloproteases，MMP1，2和3)，帕金蛋白2 (Parkin 2, PARK2)，蛋白酶体亚基β9 (Proteasome subunit beta 9, PSMB9)和抗分解代谢基因组织抑制剂金属蛋白酶(Tissue inhibitor Metalloproteinases, TIMPs)等有利于分解代谢并对IVDD起促进作用。其他已知与IVDD发病相关的遗传多态性包括维生素D受体(vitamin D receptor, VDR)和生长/分化因子5 (growth/differentiation factor 5, GDF-5)。Seki等报道称单核苷酸多态性可抑制生长因子，比如转化生长因子β (transforming growth factor beta, TGF-β) [<xref ref-type="bibr" rid="hanspub.38157-ref6">6</xref>]。Videman等研究了25个与椎间盘干燥，膨胀以及高度变小密切相关的结构、降解和炎症候选基因，揭示了椎间盘变性的多基因条件 [<xref ref-type="bibr" rid="hanspub.38157-ref7">7</xref>]。</p><p>IVDD的发病机理：环境因素、遗传因素、营养因素导致椎间盘退变进而改变细胞表型(增加基质金属蛋白酶、蛋白聚糖酶)、炎症(增加细胞因子水平)、增加细胞衰老、死亡。细胞因子通过刺激引发炎症级联反应导致椎间盘细胞中的一系列致病反应可能促进细胞自噬，衰老和凋亡。有研究表明IL-1β，IL-1R和TNFα在退化的椎间盘组织中表达增加并介导分解代谢作用，降低蛋白多糖的产生，增加MMP的表达 [<xref ref-type="bibr" rid="hanspub.38157-ref8">8</xref>]。ECM降解主要是由于基质金属蛋白酶的过度表达导致NP细胞脱水，聚集蛋白聚糖、胶原蛋白丧失和间盘机械功能损伤 [<xref ref-type="bibr" rid="hanspub.38157-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref9">9</xref>]。</p><p>细胞衰老是细胞周期的自然过程通过端粒加帽来停止细胞分裂 [<xref ref-type="bibr" rid="hanspub.38157-ref10">10</xref>]。开普勒等人发现IVDD的发展与IVDD细胞衰老有关，得到了冯等人的支持。他们表明当衰老的椎间盘细胞经历表型转变以及通过降低ECM的产量并且加强ECM降解来破坏间盘ECM合成代谢和分解代谢之间的平衡时从脱敏椎间盘中分离的NP细胞增殖较慢并呈现出细胞衰老、椎间盘退变加速 [<xref ref-type="bibr" rid="hanspub.38157-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref12">12</xref>]。细胞凋亡是一种重要的细胞死亡类型，在退变过程中被认为是至关重要的 [<xref ref-type="bibr" rid="hanspub.38157-ref13">13</xref>]。有关了解并制定潜在应对IVDD的治疗策略的研究正在进行。</p><p>IVDD的形态学，物理学和机械性变化，如椎间盘的高度和含水量减少，膨胀，神经受压，失去灵活性和弹性 [<xref ref-type="bibr" rid="hanspub.38157-ref14">14</xref>]。IVDD重要的病理特征是存在促炎介质，并且进行性地失去活性NP或AF细胞数，ECM以及改变正常椎间盘细胞的表型。NP细胞或AF细胞的丢失可能是由于过量产生细胞因子引起的，例如椎间盘中存在T细胞和中性粒细胞产生的肿瘤坏死因子α (tumor necrosis factor alpha, TNF-α)，白细胞介素(Interleukins，L-1α/β，2，4，6，8，10和17)，干扰素γ (Interferon gamma, IFN-γ)，趋化因子，巨噬细胞前列腺素(prostaglandin, PGE2) [<xref ref-type="bibr" rid="hanspub.38157-ref15">15</xref>]。</p><p>IVDD是一种以NP中蛋白多糖和水合作用进行性减少为特征的慢性过程，随之而来的是机械稳定性和减震器功能的损失，随后导致骨赘形成，脊柱节段运动减少 [<xref ref-type="bibr" rid="hanspub.38157-ref16">16</xref>]。IVDD经常发生无症状，在许多情况下，它与坐骨神经痛，椎间盘突出，椎管狭窄，脊柱侧弯和退行性脊柱侧凸有关。IVDD也影响邻近组织作为肌肉和韧带，它也会影响日常生活中脊柱承受正常生理负荷的能力 [<xref ref-type="bibr" rid="hanspub.38157-ref17">17</xref>]。</p><p>目前针对IVDD的治疗包括保守措施和手术。不管在这些治疗方案中，慢性LBP的持续存在限制了患者的生理功能和生活质量。治疗IVDD的理想方法是将椎间盘的细胞外基质成分恢复到健康的状态 [<xref ref-type="bibr" rid="hanspub.38157-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref19">19</xref>]。在这篇论述中，我们概述了治疗IVDD的策略及其作用。</p></sec><sec id="s7"><title>3. 目前针对IVDD的治疗</title><p>IVDD的保守治疗方法包括卧床休息，非甾体类抗炎药，肌松药，热敷以及物理治疗。介入治疗方法包括硬膜外类固醇药物注射、神经根阻滞术以及外科手术，其中外科手术又包括椎间盘切除术，椎间植骨融合术和椎间盘置换等。持续的疼痛感可能是由于磁共振成像(MRI)确认的神经压迫 [<xref ref-type="bibr" rid="hanspub.38157-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref20">20</xref>]。疼痛症状的缓解可以通过使用各类抗炎药物如非甾体抗炎药、类固醇、肌松药以及阿片类药物来实现 [<xref ref-type="bibr" rid="hanspub.38157-ref17">17</xref>]。这些药物虽然能在短期内有效地缓解腰背痛的症状，但对阻止椎间盘退变的进展起不到任何作用 [<xref ref-type="bibr" rid="hanspub.38157-ref21">21</xref>]。当保守治疗效果不佳的时候，手术治疗则应该是首选。但手术治疗仍有一定的缺点，例如：对原有结构的破坏、原有机械性能的部分丧失、具有一定的复发率以及邻近节段的退变。</p><p>保守治疗和手术治疗所达到的疗效有限，并且它们在大多数人中获得的疗效缺乏可持续性和长期性，因为它们的目的是缓解临床症状而不是减缓或阻止椎间盘退变的过程 [<xref ref-type="bibr" rid="hanspub.38157-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref23">23</xref>]。</p><p>对椎间盘退变机制研究的进步使得人们得以发现阻止椎间盘退变、促进椎间盘再生的新的治疗方法，这其中就包含从分子水平出发来解决这个问题以及改变级联过程。 促进椎间盘再生的方法主要分为三类：(1) 生长因子疗法，(2) 细胞治疗，(3) 基因疗法。</p></sec><sec id="s8"><title>4. 生长因子治疗</title><p>生长因子治疗是将生物因子注射到椎间盘中，以此来促进基质合成，抑制炎症，从而实现延缓退变的作用 [<xref ref-type="bibr" rid="hanspub.38157-ref24">24</xref>]。生长因子的本质是肽或多肽，其通过特殊的跨膜受体结合于细胞膜从而发挥其作用，如刺激细胞增殖、分化、凋亡等，也调控着各种细胞(软骨细胞、成纤维细胞、内皮细胞等)产生的基质代谢。包括转化生长因子、骨形态发生蛋白(bone morphogenic proteins, BMPs)、胰岛素样生长因子等在内的多种生长因子均可应用于椎间盘退行性变的修复过程 [<xref ref-type="bibr" rid="hanspub.38157-ref25">25</xref>]。</p><p>Thompson等人报道了生长因子(the growth factors, TGF-β1)的外源性给药首次在一个动物模型获得成功并报道了NP细胞的蛋白多糖的合成增加。许多体内外生长因子或蛋白质如骨形态发生蛋白(BMP-2和7)、TGF-β、碱性成纤维细胞生长因子(basic fibroblast growth Factor, bFGF)、生长/分化因子5 (growth/differentiate factor 5, GDF-5)、表皮生长因子(epidermal growth factor, EGF)、胰岛素样生长因子1 (insulin like growth factor 1, IGF-1)等被报道诱导ECM组分的合成。</p><p>富含血小板的血浆(Platelet-rich plasma, PRP)含有多种预期作为治疗性生长因子组合的蛋白质和生长因子，能够调节细胞功能以及改善组织微环境，并且在促进受损组织再生的过程中起到十分重要的作用。有研究表明：兔自体PRP凝胶与ADCCs构建的复合体可以使体外培养的细胞向类髓核样细胞分化 [<xref ref-type="bibr" rid="hanspub.38157-ref26">26</xref>]。陈等人研究表明PRP具有促进NP再生的治疗作用并促使信使核糖核酸(mRNAs)表达增加，参与软骨形成和基质积累 [<xref ref-type="bibr" rid="hanspub.38157-ref27">27</xref>]。目前，诸多研究结果表明PRP可以用作促进椎间盘修复的治疗。但事实上并不是生长因子本身能够改变退变椎间盘的生物学特性，关键是要看退行性变的椎间盘细胞对生长因子的反应性。再者，如果没有充分的营养供应，即使有生长因子的刺激，髓核和纤维环细胞也无法存活。生长因子的剂量，注射频度，方式和安全性都需要更深入的研究，否则将不能应用于临床。虽然生长因子在椎间盘退变的临床应用研究上尚存在许多困难，但其前景仍然是光明的 [<xref ref-type="bibr" rid="hanspub.38157-ref25">25</xref>]。</p></sec><sec id="s9"><title>5. 细胞疗法</title><p>细胞疗法以再生理论为基础，认为疾病的发生很多是因为大量正常细胞的衰老、死亡。因此，补充正常的细胞将会起到治疗的作用。细胞疗法通过将体细胞、干细胞等导入到损伤或退变的组织，如将髓核细胞或骨髓间充质干细胞注入退变的椎间盘内，提高局部正常细胞的绝对量，以此达到修复和治疗的目的 [<xref ref-type="bibr" rid="hanspub.38157-ref28">28</xref>]。</p><p>将外源细胞导入椎间盘用于治疗IVDD的方法已被广泛研究 [<xref ref-type="bibr" rid="hanspub.38157-ref23">23</xref>]，适用于细胞替代的细胞类别包括自体椎间盘细胞以及干细胞。用于细胞治疗的关节软骨细胞在表型上和椎间盘细胞相似，并且能够产生II型胶原和蛋白多糖。但与NP细胞相比，胶原蛋白和蛋白多糖的比例相对较低，它们或许不能作为优良的替代细胞来源 [<xref ref-type="bibr" rid="hanspub.38157-ref29">29</xref>]。</p><p>干细胞属于未分化型细胞，不同于特定细胞，因此广泛用于细胞疗法。 干细胞处于休眠状态，它们在扩散期间自我更新。以干细胞为基础基于椎间盘退变的始发因素的治疗为椎问盘退变性疾病提供了一种新的治疗思路 [<xref ref-type="bibr" rid="hanspub.38157-ref30">30</xref>]。Hoyland和Richardson发现了不同干细胞在椎间盘再生中的作用。干细胞中各种各样在再生研究中使用的是间充质干细胞、诱导多能干细胞、造血干细胞及胚胎干细胞，体内外研究报道表明干细胞疗法具有促进退变椎间盘恢复的功效，将干细胞应用于椎间盘退变性疾病的治疗有巨大的前景，但其长期疗效仍需进一步研究 [<xref ref-type="bibr" rid="hanspub.38157-ref30">30</xref>]。</p><p>细胞注射存在一定的局限性，因为有可能会出现细胞渗漏和骨赘形成。 为了消除这些局限性，基于组织工程的细胞疗法应运而生。 组织工程与细胞、生物支架以及生物活性物质联合使用。该支架可以注射形式用于微创治疗。</p></sec><sec id="s10"><title>6. 基因治疗</title><p>基因治疗是将目标基因通过某种途径导入靶细胞中，在靶细胞中表达蛋白质，进而发挥作用。基因治疗在体内需通过适宜的载体来发挥作用，也可利用离体靶细胞来进行，过程包括去除、培养、遗传改变，最后重新植入 [<xref ref-type="bibr" rid="hanspub.38157-ref31">31</xref>]。载体包括两种类型：病毒载体以及非病毒载体。病毒是极为常用的载体，诸多基因治疗方面的研究都使用了病毒载体，载体病毒包括慢病毒、腺病毒以及腺相关病毒。</p><p>慢病毒是十分有效的基因传递载体，因为它们可以将遗传信息导入宿主细胞的DNA中，如结缔组织生长因子(Connective tissue growth factor, CTGF)、TGF-β3以及TIMP-1通过慢病毒载体进入退变椎间盘后，II型胶原和蛋白多糖合成增加。</p><p>腺病毒载体在基因治疗中被广泛应用，并且具备感染非分裂细胞的优点并且能有效地帮助基因在体内外模型中短暂地高水平表达。肖剑证明了TGF-β基因可以在髓核细胞中持续而大量地表达，并能刺激产生蛋白多糖，进而使髓核含水量增加，起到阻止椎间盘退变的作用，同时还可以调节II型胶原的合成。 [<xref ref-type="bibr" rid="hanspub.38157-ref32">32</xref>] 保罗等研究了SOX-9基因通过腺病毒载体转染人类退变的椎间盘并发现了II型胶原合成增加 [<xref ref-type="bibr" rid="hanspub.38157-ref33">33</xref>]。</p><p>用腺病毒载体将GDF-5基因转入IVDD的小鼠体内，其NP、AF细胞的增殖以及细胞外基质的沉积均增加 [<xref ref-type="bibr" rid="hanspub.38157-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref35">35</xref>]。腺病毒载体转染的人潜伏膜蛋白1 (latent membrane protein 1, LMP-1)基因在兔中的表达致使蛋白多糖和骨形成蛋白(BMP-2、7)的mRNA水平增高 [<xref ref-type="bibr" rid="hanspub.38157-ref36">36</xref>]。Moon等研究了腺病毒、BMP-2、IGF-1、BMP-12和TGF-β组成的基因载体的转导，并提出了其在NP细胞中有明显的促合成代谢作用 [<xref ref-type="bibr" rid="hanspub.38157-ref37">37</xref>]。王珏等证明了AdvBMP-2转染兔退变椎间盘髓核细胞后，可使髓核细胞中Sox9的含量增加，BMP-2可能通过调节Sox9基因的表达对退变的椎间盘产生修复作用 [<xref ref-type="bibr" rid="hanspub.38157-ref38">38</xref>]。</p><p>尽管腺病毒载体在体内和体外均可传递基因且在体内模型中的效率很高，但宿主体内的免疫反应对重复转染时的基因表达产生了显著影响 [<xref ref-type="bibr" rid="hanspub.38157-ref39">39</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref40">40</xref>]。因此，腺相关病毒载体成为了替代方案，因为其免疫原性较低并且为非致病性。腺相关病毒为插入TGF-β和BMP-2基因提供足够的空间 [<xref ref-type="bibr" rid="hanspub.38157-ref41">41</xref>]。Ren等研究了AAV介导的SOX-9和成骨蛋白-1 (Osteogenic protein-1, OP1/BMP-7)双基因共同转染兔IVD，进而得出结论：其使得II型胶原和蛋白多糖的表达增加 [<xref ref-type="bibr" rid="hanspub.38157-ref42">42</xref>]。</p><p>近期的研究表明非病毒载体基因转移系统得到了更多人的关注。病毒载体虽然有着转染高效的优点，但存在着许多安全问题，例如致突变性和全身性病毒感染。非病毒载体制备难度低且更有安全性和潜力，但是也存在着转染率低的弊端，相关研究者一直致力于提高非病毒载体的转染效率。非病毒载体转移系统指的是脂质体，DNA配体复合物以及基因枪技术等 [<xref ref-type="bibr" rid="hanspub.38157-ref43">43</xref>]。</p><p>Chung等人进行了体外转染绵羊NP细胞的研究，他使用脂质体作为非病毒载体传递端粒酶基因，其结果是增加ECM的表达并且延缓细胞的衰老，特别是I型和II型胶原蛋白，其延长 &gt; 9个月 [<xref ref-type="bibr" rid="hanspub.38157-ref44">44</xref>]。Nishida等使用大鼠进行体内研究，确定了微泡可增强超声基因转移技术对椎间盘的影响并报道微泡可维持转染NP细胞增强表达所转基因至少24周 [<xref ref-type="bibr" rid="hanspub.38157-ref45">45</xref>]。</p></sec><sec id="s11"><title>7. 联合治疗</title><p>联合治疗是基于细胞的基因递送疗法，其中启动子通常加入干细胞中以增加软骨基因和抑制成骨基因的表达。Feree于2000年证明了从另一来源采集的NP细胞极其细胞外基质的组合用于恢复椎间盘功能和减轻椎间盘疾病患者的疼痛 [<xref ref-type="bibr" rid="hanspub.38157-ref46">46</xref>]。张丽等人验证了慢病毒介导hTERT基因感染人髓核细胞后，人髓核细胞的基本特性无明显变化，且不具有致瘤性 [<xref ref-type="bibr" rid="hanspub.38157-ref47">47</xref>]。Xin等人证明了用载有人端粒酶逆转录酶(human telomerase reverse transcriptase, hTERT)基因的病毒载体转染犬NP细胞并移植到狗的椎间盘中，由此对椎间盘退变产生了抵抗 [<xref ref-type="bibr" rid="hanspub.38157-ref48">48</xref>]。Yi等人的另一项研究表明携带hTIMP1基因的重组腺病毒载体转染骨髓MSCs造成TIMP-1表达增加以及椎间盘退变减少 [<xref ref-type="bibr" rid="hanspub.38157-ref49">49</xref>]。使用外泌体的无细胞治疗是治疗IVDD的另一种选择。 Lu等人研究了退化后的NP细胞被骨髓间充质细胞刺激后增殖和细胞外基因表达的情况。聚集蛋白聚糖(P &lt; 0.01)、胶原蛋白II (P &lt; 0.01)和SOX-9 (P &lt; 0.05)基因的表达显着增加，细胞增殖活性得到改善 [<xref ref-type="bibr" rid="hanspub.38157-ref50">50</xref>]。</p><p>在过去十年中，通过了解其病因来治疗IVD变性的生物学方法有一个快速的发展。基因治疗被认为是一种潜在的治疗IVDD和促进IVD再生的方法，它可以提供持续的治疗效果并消除与其他疗法相关的风险和局限性。随着先进的传递载体或系统的发展，人们可以通过引入具有最小风险的特定基因来提高基因治疗的效率。</p></sec><sec id="s12"><title>8. 结论</title><p>在研究修复或再生退变椎间盘的方法之前，首先要充分了解IVDD的发病机制。退化程度是评估治疗策略和再生功效的关键。生物疗法仍然是解决椎间盘退变的重要措施。诸多研究表明生长因子可促进细胞的合成代谢并且抑制分解代谢，但其存在一定的缺陷，例如缺乏稳定性、半衰期较短。在退变的椎间盘中使用干细胞的治疗无疑为治疗IVDD提供了一个更新死亡细胞且保留细胞外矩阵的方法。虽然许多研究证明MSCs的治疗效果，但依然有诸多问题无法解决，例如细胞介导的效率，生物力学功能，营养，保留，活动，生存能力，对抗氧化标记物。细胞疗法的风险包括注入部位的感染、肿瘤的形成以及肺栓塞等，因此必须在高等哺乳动物中完成临床试验。</p><p>在近十年里，基因疗法因其通过转移治疗剂来调节IVDD的生物学过程的能力而备受关注。为了降低其毒性和其他有害结果，靶向传递是一项重大挑战。基因治疗在IVDD中的重要地位在于它不仅可以引入单基因，而且能够结合不同的基因从而获得明显的协同治疗效果，这可能对椎间盘再生产生长期疗效 [<xref ref-type="bibr" rid="hanspub.38157-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref42">42</xref>] [<xref ref-type="bibr" rid="hanspub.38157-ref51">51</xref>]。因此，基因疗法为缩小手术治疗和保守治疗之间的差距提供了新的机会。基因疗法的作用可通过临床试验来证明，可以作为对抗腰痛和IVDD的重要策略 [<xref ref-type="bibr" rid="hanspub.38157-ref52">52</xref>]。</p></sec><sec id="s13"><title>9. 研究展望</title><p>在充分了解IVDD的发病机制以后，仍然需要发挥生物疗法在解决椎间盘退变方面的作用。应重点解决生长因子、细胞、基因疗法在治疗椎间盘退变中的缺陷和弊端。充分发挥相对更安全有效的基因疗法的作用，尽量为患者提供既有效又微创的治疗方法，减轻患者对疾病治疗的顾虑，提高患者满意度。随着研究的进一步深入，未来有望为椎间盘退变提供更好的解决方案。</p></sec><sec id="s14"><title>文章引用</title><p>张嘉军,刘 勇,许德荣,郭建伟,王华聪. 椎间盘退变的机制及其治疗综述The Mechanism and Treatment of Intervertebral Disc Degeneration[J]. 临床医学进展, 2020, 10(10): 2302-2310. https://doi.org/10.12677/ACM.2020.1010347</p></sec><sec id="s15"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38157-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Mirza, S.K. and White, A.A. III (1995) Anatomy of Intervertebral Disc and Pathophysiology of Herniated Disc Disease. Journal of Clinical Laser Medicine &amp; Surgery, 13, 131-142. &lt;br&gt;https://doi.org/10.1089/clm.1995.13.131</mixed-citation></ref><ref id="hanspub.38157-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Buckwalter, J.A. (1995) Aging and Degeneration of the Human Intervertebral Disc. Spine (Phila Pa 1976), 20, 1307-1314.  
&lt;br&gt;https://doi.org/10.1097/00007632-199506000-00022</mixed-citation></ref><ref id="hanspub.38157-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Dowdell, J., Erwin, M., Choma, T., et al. (2017) Intervertebral Disk Degeneration and Repair. Neurosurgery, 80, S46-S54.  
&lt;br&gt;https://doi.org/10.1093/neuros/nyw078</mixed-citation></ref><ref id="hanspub.38157-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hemanta, D., Jiang, X.X., Feng, Z.Z., et al. (2016) Etiology for Degenerative Disc Disease. Chinese Medical Sciences Journal, 31, 185-191. &lt;br&gt;https://doi.org/10.1016/S1001-9294(16)30049-9</mixed-citation></ref><ref id="hanspub.38157-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mayer, J.E., Iatridis, J.C., Chan, D., et al. (2013) Review: Genetic Polymorphisms Associated with Intervertebral Disc Degeneration. Spine Journal, 13, 299-317. &lt;br&gt;https://doi.org/10.1016/j.spinee.2013.01.041</mixed-citation></ref><ref id="hanspub.38157-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Seki, S., Kawaguchi, Y., Chiba, K., et al. (2005) A Functional SNP in CILP, Encoding Cartilage Intermediate Layer Protein, Is Associated with Susceptibility to Lumbar Disc Disease. Nature Genetics, 37, 607-612.  
&lt;br&gt;https://doi.org/10.1038/ng1557</mixed-citation></ref><ref id="hanspub.38157-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Videman, T., Saarela, J., Kaprio, J., et al. (2009) Associations of 25 Structural, Degradative, and Inflammatory Candidate Genes with Lumbar Disc Desiccation, Bulging, and Height Narrowing. Arthritis &amp; Rheumatology, 4, 470-481.  
&lt;br&gt;https://doi.org/10.1002/art.24268</mixed-citation></ref><ref id="hanspub.38157-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Risbud, M.V. and Shapiro, I.M. (2014) Role of Cytokines in Intervertebral Disc Degeneration: Pain and Disc Content. Nature Reviews Rheumatology, 10, 44-56. &lt;br&gt;https://doi.org/10.1038/nrrheum.2013.160</mixed-citation></ref><ref id="hanspub.38157-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Rizvi, M.R. (2015) Novel Treatment Strategies for Intervertebral Disc Degeneration. Saudi Journal for Health Sciences, 4, 5-15. &lt;br&gt;https://doi.org/10.4103/2278-0521.151403</mixed-citation></ref><ref id="hanspub.38157-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hayflick, L. (1965) The Limited in Vitro Lifetime of Human Diploid Cell Strains. Experimental Cell Research, 37, 614-636. &lt;br&gt;https://doi.org/10.1016/0014-4827(65)90211-9</mixed-citation></ref><ref id="hanspub.38157-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kepler, C.K., Ponnappan, R.K., Tannoury, C.A., et al. (2013) The Molecular Basis of Intervertebral Disc Degeneration. Spine Journal, 13, 318-330. &lt;br&gt;https://doi.org/10.1016/j.spinee.2012.12.003</mixed-citation></ref><ref id="hanspub.38157-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Feng, C., Liu, H., Yang, M., et al. (2016) Disc Cell Senescence in Intervertebral Disc Degeneration: Causes and Molecular Pathways. Cell Cycle, 15, 1674-1684. &lt;br&gt;https://doi.org/10.1080/15384101.2016.1152433</mixed-citation></ref><ref id="hanspub.38157-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ding, F., Shao, Z., Xiong, L., et al. (2013) Cell Death in Intervertebral Disc Degeneration. Apoptosis, 18, 777-785.  
&lt;br&gt;https://doi.org/10.1007/s10495-013-0839-1</mixed-citation></ref><ref id="hanspub.38157-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Blanquer, S.B.G., Grijpma, D.W., Poot, A.A., et al. (2015) Delivery Systems for the Treatment of Degenerated Intervertebral Discs. Advanced Drug Delivery Reviews, 84, 172-187. &lt;br&gt;https://doi.org/10.1016/j.addr.2014.10.024</mixed-citation></ref><ref id="hanspub.38157-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Molinos, M., Almeida, C.R., Caldeira, J., et al. (2015) Inflammation in Intervertebral Disc Degeneration and Regeneration. Journal of the Royal Society Interface, 12, Article ID: 20141191. &lt;br&gt;https://doi.org/10.1098/rsif.2014.1191</mixed-citation></ref><ref id="hanspub.38157-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Boni, M. and Denaro, V. (1987) Anatomo-Clinical Correlations in Cervical Spondylosis. In: Kehr, P. and Weidner, A., Eds., Cervical Spine, Springer-Verlag, Berlin, Vol. 1, 3-20. &lt;br&gt;https://doi.org/10.1007/978-3-7091-8882-8_1</mixed-citation></ref><ref id="hanspub.38157-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lotz, J.C. and Ulrich, J.A. (2006) Innervation, Inflammation, and Hypermobility May Characterize Pathologic Disc Degeneration. Review of Animal Model Data. The Journal of Bone and Joint Surgery. American Volume, 88, 76-82.  
&lt;br&gt;https://doi.org/10.2106/00004623-200604002-00016</mixed-citation></ref><ref id="hanspub.38157-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yoon, S.T. (2005) Molecular Therapy of the Intervertebral Disc. Spine Journal, 5, S280-S286.  
&lt;br&gt;https://doi.org/10.1016/j.spinee.2005.02.017</mixed-citation></ref><ref id="hanspub.38157-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Tow, B.P., Hsu, W.K., Wang, J.C., et al. (2007) Disc Regeneration: A Glimpse of the Future. Clinical Neurosurgery, 54, 122-128.</mixed-citation></ref><ref id="hanspub.38157-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Navani, A., Ambach, M.A., Wei, J.J., et al. (2017) Biologic Therapies for Intervertebral Degenerative Disc Disease: A Review of Novel Applications. Journal of Stem Cells Research, Reviews &amp; Reports, 4, 10-23.</mixed-citation></ref><ref id="hanspub.38157-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kadow, T., Sowa, G., Vo, N., et al. (2015) Molecular Basis of Intervertebral Disc Degeneration and Herniations: What Are the Important Translational Questions? Clinical Orthopaedics and Related Research, 473, 1903-1912.  
&lt;br&gt;https://doi.org/10.1007/s11999-014-3774-8</mixed-citation></ref><ref id="hanspub.38157-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Radcliff, K.E., Kepler, C.K., Jakoi, A., et al. (2013) Adjacent Segment Disease in the Lumbar Spine Following Different Treatment Interventions. Spine Journal, 13, 1339-1349. &lt;br&gt;https://doi.org/10.1016/j.spinee.2013.03.020</mixed-citation></ref><ref id="hanspub.38157-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Vadala, G., Russo, F., Ambrosio, L., et al. (2016) Stem Cells Sources for Intervertebral Disc Regeneration. World Journal of Stem Cells, 8, 185-201. &lt;br&gt;https://doi.org/10.4252/wjsc.v8.i5.185</mixed-citation></ref><ref id="hanspub.38157-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Masuda, K. and An, H.S. (2004) Growth Factors and the Intervertebral Disc. Spine Journal, 4, 330S-340S.  
&lt;br&gt;https://doi.org/10.1016/j.spinee.2004.07.028</mixed-citation></ref><ref id="hanspub.38157-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">田海泉, 李放. 生长因子在椎间盘退行性变组织修复重建中的意义[J]. 中国组织工程研究与临床康复, 2008, 12(46): 9121-9125.</mixed-citation></ref><ref id="hanspub.38157-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">马健, 李放, 任大江, 等. 富含血小板血浆凝胶复合脂肪间充质干细胞构建可注射组织工程髓[J]. 中国脊柱脊髓杂志, 2011(5): 353-357.</mixed-citation></ref><ref id="hanspub.38157-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W.H., Lo, W.C., Lee, J.J., et al. (2006) Tissue-Engineered Intervertebral Disc and Chondrogenesis Using Human Nucleus Pulposus Regulated through TGF-beta1 in Platelet-Rich Plasma. Journal of Cellular Physiology, 209, 744-754.  
&lt;br&gt;https://doi.org/10.1002/jcp.20765</mixed-citation></ref><ref id="hanspub.38157-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">王彦超, 席志鹏, 谢林. 细胞疗法是修复退变椎间盘最有前景的技术[J]. 中国组织工程研究, 2017, 21(20): 3234-3240.</mixed-citation></ref><ref id="hanspub.38157-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Mwale, F., Roughley, P., Antoniou, J., et al. (2004) Distinction between the Extracellular Matrix of the Nucleus Pulposus and Hyaline Cartilage: A Requisite for Tissue Engineering of Intervertebral Disc. European Cells &amp; Materials, 8, 58-63. &lt;br&gt;https://doi.org/10.22203/eCM.v008a06</mixed-citation></ref><ref id="hanspub.38157-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">南利平, 冯新民, 张亮, 等. 干细胞在椎间盘退变生物学治疗中的研究进展[J]. 中华损伤与修复杂志(电子版), 2018, 13(2): 134-138.</mixed-citation></ref><ref id="hanspub.38157-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Sobajima, S., Kim, J.S., Gilbertson, L.G., et al. (2004) Gene Therapy for Degenerative Disc Disease. Gene Therapy, 11, 390-401. &lt;br&gt;https://doi.org/10.1038/sj.gt.3302200</mixed-citation></ref><ref id="hanspub.38157-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">肖剑. 重组腺病毒介导的人转化生长因子β1基因调节椎问盘生物功能的实验研究[D]: [博士学位论文]. 上海: 第二军医大学, 2002.</mixed-citation></ref><ref id="hanspub.38157-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Paul, R., Haydon, R.C., Cheng, H.W., et al. (2003) Potential Use of Sox9 Gene Therapy for Intervertebral Degenerative Disc Disease. Spine (Phila Pa 1976), 28, 755-763. &lt;br&gt;https://doi.org/10.1097/01.BRS.0000058946.64222.92</mixed-citation></ref><ref id="hanspub.38157-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Kroeber, M., Hanke, M., et al. (2004) Release of Active and Depot GDF-5 after Adenovirus Mediated over Expression Stimulates Rabbit and Human Intervertebral Disc Cells. Journal of Molecular Medicine, 82, 126-134.  
&lt;br&gt;https://doi.org/10.1007/s00109-003-0507-y</mixed-citation></ref><ref id="hanspub.38157-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Cui, M., Wan, Y., Anderson, D.G., et al. (2008) Mouse Growth and Differentiation Factor-5 Protein and DNA Therapy Potentiates Intervertebral Disc Cell Aggregation and Chondrogenic Gene Expression. Spine Journal, 8, 287-295.  
&lt;br&gt;https://doi.org/10.1016/j.spinee.2007.05.012</mixed-citation></ref><ref id="hanspub.38157-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Yoon, S.T., Park, J.S., Kim, K.S., et al. (2004) ISSLS Prize Winner: LMP-1 Upregulates Intervertebral Disc Cell Production of Proteoglycans and BMPs in Vitro and in Vivo. Spine, 29, 2603-2611.  
&lt;br&gt;https://doi.org/10.1097/01.brs.0000146103.94600.85</mixed-citation></ref><ref id="hanspub.38157-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Moon, S.H., Nishida, K., Gilbertson, L.G., et al. (2008) Biologic Response of Human Intervertebral Disc Cells to Gene Therapy Cocktail. Spine (Phila Pa 1976), 33, 1850-1855. &lt;br&gt;https://doi.org/10.1097/BRS.0b013e31817e1cd7</mixed-citation></ref><ref id="hanspub.38157-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">王珏, 王义生, 刘宏建. 腺病毒介导的骨形态发生蛋白-2对兔退变椎间盘组织Sox9基因的影响[J]. 中华实验外科杂志, 2011, 28(8): 1378-1380.</mixed-citation></ref><ref id="hanspub.38157-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Douglas, J.T. (2007) Adenoviral Vectors for Gene Therapy. Molecular Biotechnology, 36, 71-80.  
&lt;br&gt;https://doi.org/10.1007/s12033-007-0021-5</mixed-citation></ref><ref id="hanspub.38157-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Tripathy, S.K., Black, H.B. and Goldwasser, E. (1996) Immune Responses to Transgene-Encoded Proteins Limit the Stability of Gene Expression after Injection of Replication-Defective Adenovirus Vectors. Nature Medicine, 2, 545-550.  
&lt;br&gt;https://doi.org/10.1038/nm0596-545</mixed-citation></ref><ref id="hanspub.38157-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Lattermann, C., Oxner, W.M. and Xiao, X. (2005) The Adeno Associated Viral Vector as a Strategy for Intradiscal Gene Transfer in Immune Competent and Pre-Exposed Rabbit. Spine (Phila Pa 1976), 30, 497-504.  
&lt;br&gt;https://doi.org/10.1097/01.brs.0000154764.62072.44</mixed-citation></ref><ref id="hanspub.38157-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Ren, S., Liu, Y. and Ma, J. (2013) Treatment of Rabbit Intervertebral Disc Degeneration with Co-Transfection by Adeno-Associated Virus-Mediated SOX9 and Osteogenic Protein-1 Double Genes in Vivo. International Journal of Molecular Medicine, 32, 1063-1068. &lt;br&gt;https://doi.org/10.3892/ijmm.2013.1497</mixed-citation></ref><ref id="hanspub.38157-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">谌平, 何成宜, 陈志英. 非病毒载体在基因治疗中的发展与应用[J]. 集成技术, 2017, 6(2): 59-65.</mixed-citation></ref><ref id="hanspub.38157-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Chung, S.A., Wei, A.Q., Connor, D.E., et al. (2007) Nucleus Pulposus Cellular Longevity by Telomerase Gene Therapy. Spine (Phila Pa 1976), 32, 1188-1196. &lt;br&gt;https://doi.org/10.1097/BRS.0b013e31805471a3</mixed-citation></ref><ref id="hanspub.38157-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Nishida, K., Doita, M., Takada, T., et al. (2006) Sustained Transgene Expression in Intervertebral Disc Cells in Vivo Mediated by Microbubble-Enhanced Ultrasound Gene Therapy. Spine (Phila Pa 1976), 31, 1415-1419.  
&lt;br&gt;https://doi.org/10.1097/01.brs.0000219945.70675.dd</mixed-citation></ref><ref id="hanspub.38157-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Ferree, B. (2003) Use of Extracellular Matrix Tissue to Preserve Cultured Cell Phenotype. Google Patents, 2003-02-06.</mixed-citation></ref><ref id="hanspub.38157-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">张丽, 关晓明, 马迅, 等. 人端粒酶反转录酶基因感染对人髓核细胞基本特性的影响[J]. 中国药物与临床, 2013, 13(Z1): 1-3.</mixed-citation></ref><ref id="hanspub.38157-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Xin, H., Zhang, C., Wang, D., et al. (2013) Tissue-Engineered Allograft Intervertebral Disc Transplantation for the Treatment of Degenerative Disc Disease: Experimental Study in a Beagle Model. Tissue Engineering Part A, 19, 143-151.  
&lt;br&gt;https://doi.org/10.1089/ten.tea.2012.0255</mixed-citation></ref><ref id="hanspub.38157-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Yi, Z., et al. (2014) Effects of Transplantation of hTIMP1-Expressing Bone Marrow Mesenchymal Stem Cells on the Extracellular Matrix of Degenerative Intervertebral Discs in an in Vivo Rabbit Model. Spine, 39, E669-E675.  
&lt;br&gt;https://doi.org/10.1097/BRS.0000000000000316</mixed-citation></ref><ref id="hanspub.38157-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Lu, K., Li, H., Yang, K., et al. (2017) Exosomes as Potential Alternatives to Stem Cell Therapy for Intervertebral Disc Degeneration: In-Vitro Study on Exosomes in Interaction of Nucleus Pulposus Cells and Bone Marrow Mesenchymal Stem Cells. Stem Cell Research &amp; Therapy, 8, 108. &lt;br&gt;https://doi.org/10.1186/s13287-017-0563-9</mixed-citation></ref><ref id="hanspub.38157-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Ren, X.F., Diao, Z.Z., Xi, Y.M., et al. (2015) Adeno-Associated Virus-Mediated BMP-7 and SOX9 in Vitro Co-Transfection of Human Degenerative Intervertebral Disc Cells. Genetics and Molecular Research, 14, 3736-3744.  
&lt;br&gt;https://doi.org/10.4238/2015.April.22.1</mixed-citation></ref><ref id="hanspub.38157-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Li, W., Wang, P., Zhang, Z., et al. (2017) MiR-184 Regulates Proliferation in Nucleus Pulposus Cells by Targeting GAS1. World Neurosurgery, 97, 710-715. &lt;br&gt;https://doi.org/10.1016/j.wneu.2016.01.024</mixed-citation></ref></ref-list></back></article>